662 related articles for article (PubMed ID: 16038246)
1. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years.
Sharma P; Mukherjee R; Talwar GP; Sarathchandra KG; Walia R; Parida SK; Pandey RM; Rani R; Kar H; Mukherjee A; Katoch K; Benara SK; Singh T; Singh P
Lepr Rev; 2005 Jun; 76(2):127-43. PubMed ID: 16038246
[TBL] [Abstract][Full Text] [Related]
2. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis.
Katoch K; Singh P; Adhikari T; Benara SK; Singh HB; Chauhan DS; Sharma VD; Lavania M; Sachan AS; Katoch VM
Vaccine; 2008 Feb; 26(9):1228-34. PubMed ID: 18243430
[TBL] [Abstract][Full Text] [Related]
3. Induction of lepromin positivity and immunoprophylaxis in household contacts of multibacillary leprosy patients: a pilot study with a candidate vaccine, Mycobacterium w.
Sharma P; Kar HK; Kaur H; Misra RS; Mukherjee A; Mukherjee R; Rani R
Int J Lepr Other Mycobact Dis; 2000 Jun; 68(2):136-42. PubMed ID: 11036493
[TBL] [Abstract][Full Text] [Related]
4. Induction of lepromin positivity by a candidate anti-leprosy vaccine Mycobacterium w in lepromin negative healthy contacts of multibacillary leprosy patients.
Kar HK; Sharma AK; Misra RS; Zaheer SA; Mukherjee A; Mukherjee R; Beena KR; Kaur H; Nair SK; Talwar GP
Indian J Lepr; 1992; 64(4):495-500. PubMed ID: 1308525
[TBL] [Abstract][Full Text] [Related]
5. Comparative leprosy vaccine trial in south India.
Gupte MD; Vallishayee RS; Anantharaman DS; Nagaraju B; Sreevatsa ; Balasubramanyam S; de Britto RL; Elango N; Uthayakumaran N; Mahalingam VN; Lourdusamy G; Ramalingam A; Kannan S; Arokiasamy J
Indian J Lepr; 1998; 70(4):369-88. PubMed ID: 10189587
[TBL] [Abstract][Full Text] [Related]
6. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
Kaur I; Dogra S; Kumar B; Radotra BD
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
[TBL] [Abstract][Full Text] [Related]
7. A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP.
Moet FJ; Oskam L; Faber R; Pahan D; Richardus JH
Lepr Rev; 2004 Dec; 75(4):376-88. PubMed ID: 15682975
[TBL] [Abstract][Full Text] [Related]
8. Sensitization and reactogenicity of two doses of candidate antileprosy vaccine Mycobacterium w.
Gupte MD; Vallishayee RS; Anantharaman DS; Britto RL; Nagaraju B
Indian J Lepr; 1996; 68(4):315-24. PubMed ID: 9001899
[TBL] [Abstract][Full Text] [Related]
9. Sensitization potential and reactogenicity of BCG with and without various doses of killed Mycobacterium leprae.
Gupte MD; Anantharaman DS; De Britto RL; Vallishayee RS; Nagaraju B; Kannan S; Sengupta U
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):340-52. PubMed ID: 1474275
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
11. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
12. Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis.
Ghazi Saidi K; Stanford JL; Stanford CA; Dowlati Y; Farshchi Y; Rook GA; Rees RJ
Int J Lepr Other Mycobact Dis; 1989 Mar; 57(1):45-53. PubMed ID: 2659701
[TBL] [Abstract][Full Text] [Related]
13. Patient-related factors predicting the effectiveness of rifampicin chemoprophylaxis in contacts: 6 year follow up of the COLEP cohort in Bangladesh.
Feenstra SG; Pahan D; Moet FJ; Oskam L; Richardus JH
Lepr Rev; 2012 Sep; 83(3):292-304. PubMed ID: 23356030
[TBL] [Abstract][Full Text] [Related]
14. An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis.
Chaudhury S; Hazra SK; Saha B; Mazumder B; Biswas PC; Chattopadhya D; Saha K
Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):389-94. PubMed ID: 7963911
[TBL] [Abstract][Full Text] [Related]
15. Effects of ICRC antileprosy vaccine in healthy subjects.
Chaturvedi RM; Chirmule NB; Yellapurkar MV; Shaikh SU; Deo MG
Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):657-66. PubMed ID: 3323368
[TBL] [Abstract][Full Text] [Related]
16. Prospective immunological follow-up in household contacts of Mexican leprosy patients.
Amezcua ME; Escobar-Gutiérrez A; Barba-Rubio J; Cázares JV; Mayén E; Chávez-Núñez M; Peña RC; Rodríguez R; Pastén S
Int J Lepr Other Mycobact Dis; 1990 Dec; 58(4):651-9. PubMed ID: 2280115
[TBL] [Abstract][Full Text] [Related]
17. Vaccination and skin test studies on the children of leprosy patients.
Stanford JL; Stanford CA; Ghazi Saidi K; Dowlati Y; Weiss SF; Farshchi Y; Madlener F; Rees RJ
Int J Lepr Other Mycobact Dis; 1989 Mar; 57(1):38-44. PubMed ID: 2659700
[TBL] [Abstract][Full Text] [Related]
18. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
Lopez AS; Guris D; Zimmerman L; Gladden L; Moore T; Haselow DT; Loparev VN; Schmid DS; Jumaan AO; Snow SL
Pediatrics; 2006 Jun; 117(6):e1070-7. PubMed ID: 16740809
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
[TBL] [Abstract][Full Text] [Related]
20. Intrafamilial transmission of leprosy in Vellore Town, India.
George R; Rao PS; Mathai R; Jacob M
Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):550-5. PubMed ID: 8151185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
